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THE OUTCOME OF PATIENTS UNDERGOING 
SIMULTANEOUS TRICUSPID AND LEFT-SIDED VALVE 





In the context of endemic left-sided rheumatic heart disease, tricuspid valve disease 
requiring surgical intervention merits closer scrutiny in order to analyse surgical outcomes 
with presently employed techniques. 
 
Aims 
To evaluate the results of simultaneous tricuspid valve surgery for severe functional 
tricuspid regurgitation in rheumatic heart disease at the time of left-sided valve surgery. 
 
Materials and methods 
A retrospective analysis of the perioperative and follow-up data of 30 patients who 
underwent tricuspid valve surgery with concomitant mitral and/or aortic valve replacement 
between July 2003 and December 2011 was undertaken.  
Patients referred for left-sided valve replacement surgery with clinically and 
echocardiographically documented severe functional tricuspid regurgitation in the presence 
of tricuspid annular dilatation, were submitted for combined valvular procedures.   
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Outcomes were analysed by evaluation of the perioperative and 2-year follow-up clinical 
and echocardiographic data. 
Results 
There was a statistically significant improvement in the following parameters at 6 weeks 
postoperatively:  New York Heart Association functional class, tricuspid annular diameter (p 
0.001), pulmonary artery systolic pressure (p 0.001), severity of tricuspid regurgitation 
(p<0.001) and  tricuspid transvalvular gradient (p 0.004). 
Preoperative (p 0.013) and postoperative pulmonary hypertension (p<0.002) were 
demonstrated to be associated with the development of major adverse cardiovascular 
events.  There were no identifiable predictors for the development of severe residual 
postoperative tricuspid regurgitation.  The development of severe residual postoperative 
tricuspid regurgitation was not associated with the occurrence of major adverse 
cardiovascular events.  The technique of tricuspid valve repair did not impact on the 
occurrence of major adverse cardiovascular events or on the development of severe residual 




The immediate results of tricuspid valve surgery for severe functional tricuspid regurgitation 
in rheumatic heart disease favour surgical intervention.  However, the persistence of severe 
tricuspid regurgitation adversely influenced long-term outcomes. Therefore, the 
management of rheumatic patients with functional tricuspid regurgitation should 
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encompass surgical strategies which result in a lower incidence of severe residual 



























TRICUSPID VALVE ANATOMY AND PHYSIOLOGY 
The tricuspid valve is trileaflet in structure and is the most apically placed heart valve with 
the largest orifice amongst the four valves1,2.  The valve orifice is on average between 6-
10cm2 in adults. Anatomically, the valve apparatus comprises leaflets, annulus, chordae 
tendinae and papillary muscles.   
The leaflets are designated anterior,  posterior and septal and have indentations in their free 
edges between the leaflets which are referred to as commissures:  anteroseptal, 
anteroposterior and posteroseptal.  The anterior leaflet is the largest, is usually semicircular 
in configuration and attaches to the anterior and septal walls of the right ventricle.  The 
septal leaflet lies between the posteroseptal and anteroseptal commissures and attaches to 
the septal and posterior walls of the right ventricle.  It is immediately related to the 
membranous ventricular septum.  The posterior leaflet is the smallest, lies between the 
anteroposterior and posteroseptal commissures and attaches to the posterior wall of the 







Figure 1.   Surgical anatomy of the tricuspid valve.  The triangle of Koch (TK) is indicated by the shaded area. Ant = 
anterior leaflet; AVN = atrioventricular node; CSO = coronary sinus orifice; Post = posterior leaflet; Sept = septal 
leaflet; TT = tendon of Todaro.  From:  Maurizio Taramasso, MD, Hugo Vanermen, MD, Francesco Maisano, MD, 
Andrea Guidotti, Giovanni La Canna, MD, Ottavio Alfieri, MD.  The Growing Clinical Importance of Secondary 
Tricuspid Regurgitation.J Am CollCardiol 2012; 59(8):703-710.  
 
The tricuspid annulus is oval-shaped and is located at the right atrio-ventricular junction.  
The right fibrous trigone provides attachment to the annulus only where the septal leaflet 
and anteroseptal commissure insert.  The remaining annulus is unattached and the 
connective tissue of the anterior and posterior leaflets fuse with the subendocardial tissue 
where the leaflets attach directly to the myocardium3.  This relatively unsupported area of 
the tricuspid annulus represents the site of potential annular dilatation in response to right 
ventricular dilatation.  The normal tricuspid valve annular diameter in adults is 28±5mm4. 
An average of 25 chordae tendinae insert into the tricuspid valve leaflets, providing 
attachment to the papillary muscles; 7 attach to the anterior leaflet, 6 to the posterior 
leaflet, 9 to the septal leaflet and 3 to the commissures3.  The chordae are described 
according to their respective configuration as being either fan-shaped, rough zone, basal, 
free-edge or deep3.   
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The tricuspid valve has 3 groups of integral papillary muscles, each set comprising up to 3 
muscles2.  Chordal insertion from each set of papillary muscles is into 2 adjacent leaflets.  
The anterior papillary muscle attaches to the anterior wall of the right ventricle and provides 
chordal attachment to the anterior and posterior leaflets.  The posterior papillary muscle 
attaches to the posterior wall of the right ventricle and provides chordal attachment to the  
posterior and septal leaflets.  In contrast, septal leaflet chordae tendinae arise directly from 
the interventricular septum.     
The tricuspid leaflets open in diastole with expansion of the valve orifice to facilitate atrio-
ventricular blood flow.  Systolic contraction of the orifice is intended to result in effective 
valve closure; however, a degree of regurgitation demonstrated in healthy subjects using 
colour-flow Doppler echocardiography is normal2.   
The tricuspid valve functions within a low-pressure, high-volume system1.  Peak early 
tricuspid valve inflow velocity is less than 1m/s and the mean gradient across the tricuspid 
orifice during diastole is less than 2mm Hg2.  Right ventricular systolic pressure is 20-
25mm Hg; end-diastolic pressure is equivalent to right atrial peak pressure of 3-4mm Hg1.  
Pulmonary artery systolic pressure of 20-25mm Hg is equivalent to right ventricular systolic 
pressure1; right ventricular diastolic pressure is about 10mm Hg1. 
 
TRICUSPID VALVE PATHOLOGY 
Disease of the tricuspid valve is classified as being either primary or secondary.  Primary 
disease refers to intrinsic or organic disease of the valve itself, whilst secondary disease is 
due to impaired leaflet coaptation on the basis of right ventricular or tricuspid annular 
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dilatation.  This is commonly referred to as “secondary” or “functional” tricuspid 
regurgitation and is a direct consequence of left-sided valvular disease. 
Primary disease may be a result of congenital cardiac malformations, rheumatic heart 
disease, infective endocarditis, carcinoid heart disease, cardiac tumours, trauma, 
degenerative valve disease, iatrogenic or toxic valvulopathy2. 
Secondary, or functional tricuspid regurgitation occurs in the presence of right ventricular 
hypertension, dilatation or failure, most commonly in response to advanced left-sided 
rheumatic heart valve disease2.  Functional tricuspid regurgitation is accompanied by 
annular dilatation and leaflet tethering (apical displacement of the tricuspid leaflets).  To a 
lesser, extent, functional tricuspid regurgitation occurs as a result of segmental or global 
right ventricular dysfunction; the former on an ischaemic basis and the latter due to 
cardiomyopathy. 
 
PATHOGENESIS OF FUNCTIONAL TRICUSPID REGURGITATION IN LEFT-SIDED VALVULAR 
DISEASE 
In the presence of left-sided rheumatic valvular disease, the underlying condition leads to 
the development of mitral regurgitation5.  Rheumatic heart disease may also cause mitral 
stenosis.  Both forms of mitral valve disease cause increased left atrial pressure, resulting in 
pulmonary hypertension, right ventricular dysfunction, enlargement, and eventually 
tricuspid regurgitation5.  A consequence of increased left atrial pressure is left atrial 
dilatation; a phenomenon directly related to atrial fibrillation and tricuspid annular 
dilatation5.  Tricuspid annular dilatation is considered to be the “substratum” for the 
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development of tricuspid regurgitation5.  Rheumatic heart disease may also result in organic 
disease of the tricuspid valve, and directly result in tricuspid regurgitation.   
Various mechanisms are proposed in the development of functional tricuspid regurgitation.  
Tricuspid annular dilatation and tricuspid leaflet tethering in tandem disrupt the balance 
among tricuspid leaflet size, annular orifice area and spatial orientation of the valve 
apparatus, resulting in impaired leaflet coaptation and the development of tricuspid 
regurgitation6.  The tricuspid annulus undergoes changes in three-dimensional geometry;  it 
occupies a greater area, becomes flatter and circular in shape and the annular excursion is 
diminished during the cardiac cycle7.  In summary, the normal geometric relationships of 
the tricuspid leaflets, chordae and papillary muscles are distorted by functional tricuspid 
regurgitation and right ventricular dilatation, resulting in tricuspid leaflet tethering and 
restricted coaptation7. 
 
PATHOPHYSIOLOGY OF FUNCTIONAL TRICUSPID REGURGITATION 
Tricuspid regurgitation is regarded as a progressive condition.  The right atrium and 
ventricle dilate due to volume overload.  Eventually, right ventricular systolic dysfunction 
supervenes; increased diastolic pressure is accompanied by displacement of the 
interventricular septum towards the left ventricle during diastole8.  This phenomenon has 
been termed “restriction-dilatation syndrome8,” and is characterised by elevated pressure 
and expanding volume of one chamber compressing an adjacent chamber resulting in 




ASSESSMENT OF THE SEVERITY OF TRICUSPID REGURGITATION 
Tricuspid valve analysis is mandatory in the presence of tricuspid regurgitation4.  The 
imaging modality of choice is three-dimensional transthoracic echocardiography.  Trans-
oesophageal echocardiography is recommended in the presence of suboptimal transthoracic 
echocardiographic images4.   
Various combinations of qualitative, semi-quantitative and quantitative echocardiographic 
parameters have been recognised to confer varying degrees of severity to tricuspid 
regurgitation which may be described as mild, moderate or severe4.  The qualitative 
parameters are:  tricuspid valve morphology, the size of the colour-flow regurgitant jet and 
the density of the continuous wave jet signal.  The semi-quantitative parameters are:  width 
of the vena contracta, proximal isovelocity surface area radius, hepatic vein flow and 
tricuspid inflow characteristics.  The quantitative parameters are:  effective regurgitant 
orifice area dimension and combined regurgitant volume and right atrial/right 
ventricular/inferior vena caval dimension.   
 
IMPACT OF TRICUSPID REGURGITATION ON SURVIVAL 
Moderate or greater tricuspid regurgitation has been demonstrated to confer decreased 
survival in men regardless of left ventricular ejection fraction or pulmonary artery pressure9.  
Severe tricuspid regurgitation has been associated with a poor prognosis, independent of 
age, biventricular systolic function, right ventricular size or inferior vena caval dilatation9.  
Mild-or-less tricuspid regurgitation is not associated with adverse outcome9.  The exact 




PROGNOSTIC IMPLICATIONS OF FUNCTIONAL TRICUSPID REGURGITATION IN PATIENTS 
WITH MITRAL VALVE DISEASE 
The presence of tricuspid regurgitation following mitral valve replacement predicts poor 
outcome10.   
Moderate-to-severe tricuspid regurgitation during follow-up has been found to be an 
independent predictor of New York Heart Association functional class 3 or 4 heart failure, 
heart failure-related death, and all-cause mortality during follow-up11.  A 5-year survival 
rate of 50% in rheumatic heart disease patients with the clinical and echocardiographic 
features of severe tricuspid regurgitation following mitral valve surgery has been 
documented12.  Significant tricuspid regurgitation necessitating tricuspid valve surgery has 
been shown to predict poor survival in patients undergoing left-sided valve surgery13.  
Functional tricuspid regurgitation occurring late after mitral valve surgery has been 
demonstrated to be related to diminished overall long-term survival and a worse long-term 
functional status; in addition, re-operation for late severe functional tricuspid regurgitation 
has been associated with a uniformly poor prognosis and high early and late mortality14.  
There is also evidence that untreated tricuspid regurgitation following mitral valve 
replacement is associated with a diminished cardiac output response to exercise which 
deteriorates in the face of progressive tricuspid valve dysfunction, eventually requiring 







BASIS FOR INTERVENTION IN FUNCTIONAL TRICUSPID REGURGITATION 
Functional tricuspid regurgitation was previously regarded as a benign condition that 
resolved spontaneously after correction of left-sided valvular heart disease.  Left untreated, 
it is now known not to resolve after mitral valve surgery in a high proportion of patients, 
causing persistence of moderate or severe tricuspid regurgitation at mid-term follow-up 
and impacting adversely on survival15.   
Reoperation on the tricuspid valve for persistent tricuspid regurgitation after mitral valve 
surgery is associated with a high surgical risk; the presence of irreversible right ventricular 
dysfunction prior to reoperation may be the reason for poor long-term results8.   Correction 
of tricuspid annular dilatation by adoption of a stage-specific therapeutic strategy as the 
cornerstone of intervention in functional tricuspid regurgitation is believed to offer 
improved short-and long-term outcomes15.  The emergence of a need to pre-emptively 
identify patients at risk of progression of tricuspid regurgitation has been in response to 
poor outcomes of patients undergoing reoperative surgery for late severe tricuspid 
regurgitation16.   
 
MANAGEMENT OF FUNCTIONAL TRICUSPID REGURGITATION IS CONTENTIOUS 
In an early report, it has been suggested that tricuspid regurgitation regresses after mitral 
valve replacement and that concomitant tricuspid surgery is not required10.  This view is no 
longer held with the emergence of new evidence14.   
In contemporary surgical practice, however, despite the existence of a general agreement 
for simultaneous interventional tricuspid valve surgery in cases of severe regurgitation in 
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the setting of left-sided valve surgery, the current guidelines offer unclear indications for 
patients with mild-to-moderate tricuspid regurgitation17.   
Tricuspid valve repair based on tricuspid annular dilatation has been shown to improve 
functional status irrespective of the degree of regurgitation18.  This is counterbalanced by a 
high rate of recurrence of tricuspid regurgitation after interventional surgery, independent 
of the surgical technique19.  In addition, there is disagreement over the best surgical 
technique for tricuspid valve repair5.   
A review of the guideline indications for concurrent tricuspid valve repair demonstrates that 
severe tricuspid regurgitation at the time of mitral valve surgery is the only definite 
indication for intervention (Class 1)20.  There is no apparent consensus on the management 
of mild functional tricuspid regurgitation; similarly, the management of moderate-to-severe 
tricuspid regurgitation is open to interpretation19,20.  There have even been proponents for 
“prophylactic” annuloplasty in order to avoid disease progression18. 
The enduring questions that guide surgical decision-making in functional tricuspid 
regurgitation may be summarised thus8: When should one repair or replace the tricuspid 
valve in association with surgery for left-sided valve disease?  What should be done with 
mild-to-moderate tricuspid regurgitation?  How does one predict those patients who will 







PRINCIPLES OF SURGICAL MANAGEMENT OF FUNCTIONAL TRICUSPID REGURGITATION 
The principal determinants of tricuspid regurgitation must be addressed for surgical 
treatment of functional tricuspid regurgitation to be effective:  increased right ventricular 
afterload, annular dilatation and right ventricular dysfunction20.   
Correction of the left-sided valvular lesion and left ventricular dysfunction will result in 
reduced pulmonary hypertension and reduced right ventricular afterload.  Correction of the 
left-sided valvular lesion, elimination of tricuspid regurgitation and reduction of pulmonary 
hypertension will improve right ventricular dysfunction.   
The foundation of current surgical therapy for severe functional tricuspid regurgitation is 
tricuspid valve repair which addresses annular dilatation and restores annular geometry, 
facilitating leaflet coaptation20.  The surgical armamentarium for functional tricuspid 
regurgitation is divided between tricuspid repair techniques and tricuspid valve 
replacement.  Tricuspid valve repair procedures address functional tricuspid regurgitation at 
3 anatomical levels:  annulus, commissure and leaflet21 and although many techniques have 
been described, most are derivatives of 2 fundamental approaches:  suture annuloplasty and 
ring annuloplasty20.  Tricuspid valve repair is considered preferable to replacement 
whenever technically possible.  Tricuspid valve replacement is usually reserved for tricuspid 








OVERVIEW AND LITERATURE REVIEW 
 
INCIDENCE OF FUNCTIONAL TRICUSPID REGURGITATION IN MITRAL VALVE DISEASE 
Functional tricuspid regurgitation is reported to occur relatively frequently in the presence 
of mitral valve disease in the surgical literature.   
More than a third of patients with mitral stenosis have at least moderate tricuspid 
regurgitation10.  In patients with rheumatic heart disease, clinically severe tricuspid 
regurgitation has been documented in 23% to 37% of patients after mitral valve 
replacement10.   
In rheumatic patients, echocardiographically moderate or severe late tricuspid regurgitation 
has been reported in up to 68% of patients and is characteristically diagnosed late after 
mitral valve replacement, 10 years on average10. 
 
PROGNOSIS OF FUNCTIONAL TRICUSPID REGURGITATION IN MITRAL VALVE DISEASE 
Only as recently as 2008, has the prognostic role of untreated functional tricuspid 
regurgitation been delineated22.  The authors concluded that moderate-or-more functional 
tricuspid regurgitation, left untreated at the time of surgical intervention for mitral 
regurgitation, would impair 5-year survival, as well as survival in New York Heart 
Association functional class 1-2, based on the premise that functional tricuspid 
regurgitation is likely to progress.   
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In three retrospective studies18,23,24, it has been shown that leaving functional tricuspid 
regurgitation untreated at the time of mitral valve surgery results in more tricuspid 
regurgitation at follow-up despite correction of co-existent left-sided disease.   
 
PREDICTORS OF RESIDUAL TRICUSPID REGURGITATION AFTER MITRAL VALVE SURGERY 
The uncertainty whether preoperative functional tricuspid regurgitation will regress or 
progress after surgery challenges surgical decision-making during intervention for left-
sided valve disease.   
In a series of 174 patients undergoing mitral valve surgery without tricuspid valve 
intervention, severe tricuspid regurgitation was documented in 16% of patients late after 
mitral valve replacement24.  The risk factors identified for residual tricuspid regurgitation 
were:  a left atrial diameter >60mm and the presence of atrial fibrillation.  Mechanisms 
postulated to be responsible for the high prevalence of late tricuspid regurgitation were:  
persistent pulmonary hypertension, right ventricular dysfunction, tricuspid annular 
dilatation, a postoperative increase in cardiac output resulting in diminished regression of 
tricuspid annular dilatation and the presence of more-than-mild tricuspid regurgitation. 
In a study of 70 patients with functional ischaemic mitral regurgitation who underwent 
coronary revascularization and mitral valve repair, preoperative functional tricuspid 
regurgitation was present in 30% of cases25.  In 57% of the cases, the tricuspid regurgitation 
was ignored and post surgery the incidence of tricuspid regurgitation increased to 50% 
irrespective of whether it was repaired or ignored.  The presence of tricuspid regurgitation 
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increased during follow-up, peaking at 70% at 3 years.  Preoperative annular dilatation was 
established to be a predictor of late tricuspid regurgitation. 
Multiple clinical variables were shown to be independent risk factors for the development of 
late severe tricuspid regurgitation in 638 patients who had mild tricuspid regurgitation and 
who underwent successful left-sided valve surgery without any tricuspid procedure26.  The 
baseline risk factors were reported to be:  age, female gender, rheumatic aetiology and atrial 
fibrillation. 
The influence of subvalvar preservation techniques on the development of late severe 
tricuspid regurgitation after mitral valve replacement was investigated in 801 patients who 
did not undergo any tricuspid procedure27.  It was concluded that although early surgical 
intervention for tricuspid regurgitation may be recommended in selected patients, complete 
preservation of the mitral subvalvar apparatus and routine surgical elimination of atrial 
fibrillation could significantly reduce its incidence. 
The impact of tricuspid leaflet tethering in functional tricuspid regurgitation on recurrent or 
residual tricuspid regurgitation following tricuspid annuloplasty was studied in 39 
patients28.  Of these, 33 patients had concomitant mitral valve procedures.  Preoperative 
tricuspid leaflet tethering height and area were found to be risk factors for tricuspid repair 
failure, prompting the need for additional surgical strategies to overcome this phenomenon. 
 
GUIDELINES FOR THE MANAGEMENT OF FUNCTIONAL TRICUSPID REGURGITATION 
Guidelines from both the American College of Cardiology/American Heart Association and 
the European Society of Cardiology, assign a class 1 recommendation for tricuspid valve 
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repair in patients with severe tricuspid regurgitation undergoing left-sided valve 
surgery10,29.  The European guidelines assign a class 2a recommendation for concomitant 
tricuspid valve repair in patients with a tricuspid annular diameter >40mm or moderate 
tricuspid regurgitation29.  The American guidelines assign a class 2b recommendation for 
patients with less-than-severe tricuspid regurgitation10.  A class 2a recommendation is also 
assigned by the European guidelines for tricuspid valve repair in patients with symptomatic, 
isolated tricuspid regurgitation late after mitral and/or aortic valve surgery, on condition 
that left-sided myocardial or right ventricular dysfunction and severe pulmonary 
hypertension are absent29.  
 
SURGICAL MANAGEMENT OF FUNCTIONAL TRICUSPID REGURGITATION 
The current surgical repertoire for functional tricuspid regurgitation is divided between 
tricuspid valve repair techniques and tricuspid valve replacement.  Controversy exists over 
the best surgical technique for tricuspid valve repair5 whilst prosthetic replacement of the 
tricuspid valve is accompanied by valve-related complications.  It is always desirable to 
preserve the native tricuspid valve as far as possible, if technically feasible; hence repair 
techniques are favoured above valve replacement.    
The recurring questions in the literature with respect to decision-making in tricuspid valve 
surgery are8:  What is the choice between tricuspid valve repair and replacement?  What is 
the efficacy of different methods of repair?  What type of prosthesis is to be selected if the 
valve is replaced?   
Traditionally, the basic principles of tricuspid valve repair involve the following techniques31:  
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1.  Techniques that obliterate some of the anterior and posterior leaflet tissue whilst 
simultaneously reducing the corresponding annular dimension, constructing one or more 
pleats along its length. 
2.  Techniques that fix the anterior and posterior leaflet annulus to a partial prosthetic ring, 
which may be rigid or pliable in design and reduce the annular dimension by application of 
wide suture-spacing at the annulus and narrow suture-spacing at the ring. 
3.  Techniques that incorporate a sliding plasty of the leaflets with annular reduction, 
performed using a prosthetic ring or by the construction of pleats. 
4.  Techniques that shorten the annulus by means of an incomplete purse-string suture 
embedded in the atrioventricular junction adjacent to the anterior and posterior leaflets, 
extending from the anteroseptal to the posteroseptal commissures. 
Tricuspid valve repair procedures address functional tricuspid regurgitation at 3 anatomical 














Techniques that address tricuspid annular dilatation comprise suture annuloplasty and ring 
annuloplasty.  Refer to figure 2.   
 
 
Figure 2.  Tricuspid annular procedures.  (A) Suture annuloplasty repair: a single suture is placed around the 
tricuspid annulus, avoiding the area of the atrioventricular node. The suture is tied, completing the annuloplasty. 
(B) Ring annuloplasty repair: a sizer measuring the intertrigonal distance is used to determine the ring size. 
Multiple interrupted sutures are placed at the atrioannular junction.  From:  Maurizio Taramasso, MD, Hugo 
Vanermen, MD, Francesco Maisano, MD, Andrea Guidotti, Giovanni La Canna, MD, Ottavio Alfieri, MD.  The Growing 
Clinical Importance of Secondary Tricuspid Regurgitation.J Am CollCardiol 2012; 59(8):703-710.  
 
Suture Annuloplasty 
Suture annuloplasty techniques aimed at annular reduction are the De Vega annuloplasty 
and its modification.  The original De Vega annuloplasty plicated both the anterior and 
posterior annulus using a continuous, double-layer pledgeted non-absorbable suture 
placed in the atrio-ventricular junction adjacent to the annulus from the anteroseptal to 
posteroseptal commissures.  The sutures are then tightened to produce a purse-string 
effect, reducing the length of the anterior and posterior annuli and resulting in adequate 
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leaflet coaptation.  The desired annular reduction is best achieved using a tricuspid 
annuloplasty obturator conforming to the dimension of the septal leaflet of the tricuspid 
valve.  
The problem of suture dehiscence from the annulus was overcome by Antunes and 
Girdwood in a modification described in 1983 in which each suture was buttressed with a 
synthetic pledget8.  Although these techniques are quick, inexpensive and technically 
simple, they are less reproducible and their results are less predictable than those of ring 
annuloplasty.     
Uncertainty over the extent to which the dilated tricuspid annulus should be reduced using 
suture annuloplasty techniques has led to annular stenosis and residual tricuspid 
regurgitation postoperatively.  The development of techniques to selectively reduce the 
dilated anterior and posterior tricuspid leaflet annuli without reducing the active surface of 
the valve leaflets has been described by Yiwu and others33.  Their procedure is based on an 
exact quantitative repair technique using purpose-made tricuspid obturators to 
individualise the change in annular dimension to the physiological and anatomical 
characteristics of each patient’s tricuspid annulus and offers an alternative technique to 
ensure efficacy of tricuspid repair when an annuloplasty ring is not used. 
 
Ring Annuloplasty 
Tricuspid ring annuloplasty was described in 1971 by Carpentier where a reduction 
annuloplasty of the anterior and posterior tricuspid annulus was accomplished using a pre-
shaped rigid prosthetic ring32.   
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 In contemporary practice, tricuspid annuloplasty rings or bands may be partial or complete 
and flexible, semi-rigid or rigid in design and construction20.  The dimension of the base of 
the septal leaflet of the tricuspid valve dictates the size of the ring or band employed.  An 
additional method to determine the size of prosthesis to be used is by comparing the 
tricuspid obturator to the combined surface area of the anterior and posterior tricuspid 
leaflets20.   
Non-absorbable, pledgeted mattress sutures are placed circumferentially at the junction of 
the annulus and right ventricular free-wall, with wider suture placement on the annulus and 
narrower corresponding suture placement on the prosthetic sewing ring to produce annular 
plication predominantly along the length of the posterior leaflet.  The re-orientated 
geometry allows occlusion of the valve orifice primarily by anterior and septal leaflet tissue.  
Rigid and semi-rigid rings are believed to restore the three-dimensional geometry of the 
tricuspid annulus in a fixed systolic position (remodelling annuloplasty)20.  
The use of a partial ring or band prosthesis avoids inadvertent suture placement into the 
conduction tissue related to the septal leaflet, thereby minimizing the occurrence of 
postoperative conduction block.   These devices also stabilize the anterior and posterior 
annulus, the anatomical areas known to be most prone to dilatation.  The use of a complete 
ring confers complete protection against future annular dilatation, but carries an increased 
risk of iatrogenic conduction block.  This potential risk is minimised by placement of 
sutures through the base of the septal leaflet instead of through the annulus in the region of 
the conduction tissue.  It appears that the main benefit from employing a rigid ring over a 
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flexible band is that the dimension of the septal annulus is both normalised and effectively 
stabilised, reducing the incidence of late regurgitation. 
 
Commissural Procedures 
Suture bicuspidization commissuroplasty, a technique described by Kay and others in 1965 
transforms the tricuspid valve into a bicuspid valve structure34.  This is accomplished by 
plicating the annulus along the posterior leaflet using 2 concentric, pledgeted non-
absorbable sutures.  The sutures are tied to obliterate the posterior leaflet, producing a 
bicuspid right atrioventricular valve.  Refer to figure 3.  The disadvantage of this technique 
is that it results in posterior leaflet atrophy and does not address the tendency of the 
anterior annulus to dilate20.  There is additional technical difficulty in deciding how much of 
the posterior leaflet to plicate.   
 
 
Figure 3. Suture bicuspidization commissuroplasty.  (A) Tricuspid valve bicuspidization is accomplished by plicating 
the annulus along the posterior leaflet. (B) The sutures are tied, obliterating the posterior leaflet, creating a 
bicuspid valve.  From:  Maurizio Taramasso, MD, Hugo Vanermen, MD, Francesco Maisano, MD, Andrea Guidotti, 
Giovanni La Canna, MD, Ottavio Alfieri, MD.  The Growing Clinical Importance of Secondary Tricuspid 




The phenomenon of leaflet tethering has been described as a risk factor for failure of valve 
repair in functional tricuspid regurgitation28. Severe tethering is defined 
echocardiographically as a tethering height (the distance between the tricuspid annular 
plane and the coaptation point between the anterior and septal leaflets) greater than 8mm 
at mid-systole in a four-chamber view35.  When severe tethering is present, additional 
techniques have been described in conjunction with ring annuloplasty in order to add 
durability to the repair20.   
Dreyfuss and others pioneered a technique for treating severe tricuspid regurgitation due to 
severe tricuspid leaflet tethering by augmenting the anterior tricuspid leaflet with a patch of 
autologous pericardium35.  This manoeuvre increases the size of the anterior leaflet, hence 
its surface area of coaptation, thus permitting increased leaflet coaptation to occur in the 
presence of decreased right ventricular tension.  The repair is reinforced using a rigid 
annuloplasty ring.  The major advantage of this procedure is that leaflet coaptation is 
allowed to occur within the right ventricle at the level of the tethered septal and posterior 
leaflets, whilst simultaneously preserving leaflet mobility. 
The surgical management of complex tricuspid valve pathology has encompassed 
challenging reconstructive procedures and has been associated with suboptimal outcomes.  
A surgical technique whereby the central portion of the free edges of the tricuspid leaflets 
are sutured together to produce a “clover” shaped valve has been proposed by De Bonis and 
others to improve the efficacy of valve repair in the context of complex lesions, not 
manageable exclusively by annuloplasty36.  Refer to figure 4.  This represents a functional, 
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rather than an anatomical repair and has been postulated to be effective in any type of 
tricuspid insufficiency on the basis of complex mechanisms such as leaflet prolapse, flail or 
retraction37. Significantly, tricuspid valve competence was reported to be restored even in 
the presence of severe right ventricular dilatation and pulmonary hypertension.   
 
 
Figure 4.  The Clover technique.  The middle parts of the free edges of the tricuspid leaflets are sutured together, 
producing a clover-shaped valve.  From:  Maurizio Taramasso, MD, Hugo Vanermen, MD, Francesco Maisano, MD, 
Andrea Guidotti, Giovanni La Canna, MD, Ottavio Alfieri, MD.  The Growing Clinical Importance of Secondary 
Tricuspid Regurgitation.J Am CollCardiol 2012; 59(8):703-710.  
 
Tricuspid valve replacement 
Although preservation of the native valve whenever technically feasible is one of the tenets 
of contemporary cardiac surgery, replacement of the tricuspid valve is sometimes necessary.  
The available options for tricuspid valve replacement are either a mechanical or biological 
prosthesis or a mitral homograft.  The major operative complication is that of heart block 
arising from suture injury to the conducting tissue, hence preservation of the tricuspid 
leaflets and subvalvar apparatus is desirable in order to minimize the risk of injury.  
Everting, pledgeted mattress sutures are used for implantation of a mechanical valve and 
similar suture material is used in a supra-or-intra-annular configuration for implantation of 
a bioprosthesis. It is also recommended that the procedure be performed with the heart 
beating, employing continuous electrocardiographic monitoring in order to detect rhythm 
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disturbance arising from aberrant suture placement.  The placement of temporary epicardial 
pacing electrodes is mandatory for the pre-emptive management of potential dysrhythmias.  
Partial replacement of the tricuspid valve using mitral homograft tissue has been reported in 
the setting of right-sided infective endocarditis when repair techniques are not feasible, and 
represents an alternative to prosthetic replacement of the tricuspid valve38.  In this series, 
the tricuspid valve was reinforced using a rigid prosthetic ring. The choice of mitral, rather 
than tricuspid valve tissue for implantation is influenced by the fact that mitral tissue is of 
superior quality and has more favourable handling characteristics than tricuspid tissue.   
 
Percutaneous options 
Experimental reports describing percutaneous approaches to tricuspid valve disease in 
animals have emerged as early as 2005 when a percutaneous tricuspid valve constructed 
from a bovine jugular venous valve mounted to a self-expanding nitinol frame was deployed 
in sheep via the jugular vein30.   The anatomical structural relationships of the right atrium 
present unique challenges to this approach with respect to device placement and an 
additional consideration is that of thrombogenicity induced by the low pressure and flow 








TRICUSPID VALVE REPAIR:  LONG-TERM RESULTS  
The various techniques of tricuspid valve repair described in the literature encompass suture 
and ring annuloplasty, bicuspidization, anterior leaflet augmentation and the clover-leaf 
repair.  In the analysis of the long-term results of the various applicable techniques, it is 
mandatory to consider factors such as functional class, presence of congestive heart failure, 
recurrence of moderate-to-severe tricuspid regurgitation, event-free survival (freedom from 
thromboembolism, major bleeding event, infective endocarditis, tricuspid valve reoperation 
and death) and actuarial survival.   
In a thirty year retrospective assessment of outcome after tricuspid valve surgery, Guenther 
and colleagues discuss their findings from a series of 310 patients who underwent tricuspid 
valve repair out of a cohort of 416 consecutive patients submitted to tricuspid valve surgery 
with or without concomitant cardiac surgical procedures39.  They emphasise that patients 
who require tricuspid valve surgery constitute a high-risk group reflected by an advanced 
stage of heart disease often accompanied by severe right ventricular dysfunction.   Ten-year 
actuarial survival after tricuspid valve repair was 47% and freedom from tricuspid valve 
reoperation at the same interval was 83%.   
Carrier and co-workers reported the results of 3 surgical techniques employed in the repair 
of functional tricuspid insufficiency in 463 patients over 25 years40.  They noted a mean 5-, 
10- and 15-year patient survival of 82%, 58% and 30% respectively in the group undergoing 
suture annuloplasty; 76%, 54% and 36% survival for the corresponding period in the group 
undergoing flexible band implantation and 88% survival at 5 years for the prosthetic ring 
annuloplasty group.  The mean freedom rate from tricuspid repair failure was 95%, 93% and 
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72% at 5, 10 and 15 years respectively for the suture annuloplasty group and 97%, 87% and 
66%  at 5, 10 and 15 years for the flexible band group respectively.  At 5 years the mean 
freedom rate from repair failure for the prosthetic ring annuloplasty cohort was 94%.  They 
concluded that all 3 techniques of tricuspid valve repair resulted in a low failure rate and in 
good patient survival at long-term follow-up. 
Publishing their experience with the long-term results of triple valve surgery, Carrier and 
others described their findings in 66 patients undergoing tricuspid valve repair using a 
suture annuloplasty, flexible ring or prosthetic ring technique during simultaneous mitral 
and aortic valve replacement with either mechanical or biological prostheses, including 
reoperations41.   Patient survival at 1, 5 and 10 years averaged 80%, 75% and 41% 
respectively for patients undergoing primary surgery and 70%, 57% and 50% respectively for 
patients undergoing reoperative surgery.  They concluded that triple valve surgery results in 
acceptable long-term survival with both mechanical and biological prostheses.   
The long-term clinical outcome was investigated by Onoda and co-investigators in 45 
patients with functional tricuspid regurgitation managed by rigid ring annuloplasty42.  The 
mean follow-up was 96.7 months.  Actuarial survival at 10 years was 68.3% with satisfactory 
regression of tricuspid regurgitation and functional class.  The actuarial rate of freedom 
from tricuspid valve reoperation at 10 years was 97.5%.  Their conclusion was that rigid ring 
annuloplasty was acceptable for repair of functional tricuspid regurgitation as well as long-
term improvement in functional status. 
In a study of 110 patients undergoing a De Vega annuloplasty for functional tricuspid 
regurgitation at the time of left-sided valvular surgery, Abe and others reported their results 
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after a mean follow-up of 22 months43.   They demonstrated a significant improvement in 
haemodynamics and functional class postoperatively as well as a late mortality of 2.7%.  In 
addition, their actuarial survival rate at 10 years was 85.8% and the actuarial rate of freedom 
from tricuspid valve reoperation was 96.7%. 
Bernal and associates examined long-term outcomes after combined mitral and tricuspid 
valve repair in 153 consecutive patients with rheumatic valvular disease44.  The mean 
follow-up duration was 15.8 years.  They demonstrated poor long-term results with a late 
mortality of 60.1% and a high reoperation rate for both the mitral and tricuspid valve.  They 
concluded that the use of a prosthetic tricuspid annuloplasty ring was associated with a 
reduced incidence of tricuspid valve reoperation. 
 
TRICUSPID VALVE REPLACEMENT:   DETERMINANTS OF EARLY AND LONG-TERM 
OUTCOMES 
Poor outcomes have been historically documented following tricuspid valve replacement;    
high operative mortality rates, low rates of event-free survival and poor long-term survival.  
The preoperative factors associated with these results have been poorly understood and 
may serve to improve outcomes when selection for surgical intervention is modified 
accordingly. 
The reported early mortality following tricuspid valve replacement ranges from 8.8-25% and 
5-year actuarial survival ranges between 41-44%45.  Valve-related events described in 
relation to event-free survival in the literature include thromboembolism (including stroke), 
valve thrombosis, structural valve dysfunction, major bleeding events, infective endocarditis, 
tricuspid valve reoperation and death. 
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In a study to determine the preoperative predictors of increased mortality and adverse 
outcome after tricuspid valve replacement, Topilsky and others identified advanced heart 
failure and echocardiographic evidence of increased right ventricular filling pressure to be 
the principal determinants of early outcome and survival in 189 patients undergoing 
tricuspid valve replacement45. 
In a series of 42 consecutive patients undergoing tricuspid valve replacement, Iscan and 
colleagues reviewed their experience in a cohort with a predominance of rheumatic valve 
disease and concluded that suboptimal short and long-term outcomes are influenced by 
aetiology, clinical presentation and pulmonary vascular haemodynamic parameters46.   
Carrier and others, in a series of 97 patients undergoing tricuspid valve replacement with 
25-year follow-up data, concur that survival after tricuspid valve replacement is suboptimal, 
and is related to the clinical condition at the time of operation47. 
 
SUTURE VERSUS RING ANNULOPLASTY 
The inevitable comparison between the techniques of suture and ring annuloplasty 
accompanies virtually every review of the literature on the subject of tricuspid valve repair.   
From their series of 702 patients who underwent tricuspid valve repair utilizing either a De 
Vega or a ring annuloplasty, Tang and others sought to compare their long-term outcomes 
in patients with predominantly functional tricuspid regurgitation48.  They illustrated 
significantly better long-term survival, event-free survival, freedom from recurrent tricuspid 
regurgitation and fewer tricuspid valve reoperations in the ring annuloplasty group.  In 
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addition, they demonstrated by multivariate analysis that the use of an annuloplasty ring 
was an independent predictor of long-term survival. 
The question of whether tricuspid ring annuloplasty is the superior technique of tricuspid 
valve repair was examined in a study by Guenther and colleagues49.   Their study cohort 
included 717 patients undergoing tricuspid valve surgery, of whom 60% had a ring 
annuloplasty and 36% had a suture annuloplasty.  The aetiology was functional tricuspid 
regurgitation in 67%.  They concluded that the ring annuloplasty was associated with 
improved survival and a lower reoperation rate than suture annuloplasty. 
A direct comparison of long-term outcomes among 194 patients who underwent tricuspid 
repair for functional regurgitation using either suture or ring annuloplasty was undertaken 
by Seitelberger and others50.  Their results indicated that recurrence of tricuspid 
insufficiency and the need for tricuspid valve reoperation was greater in the suture 
annuloplasty group.  Significantly, survival in the suture annuloplasty group was lower 
during follow-up.   
Matsuyama and co-investigators compared the results of 45 patients managed by either 
suture or ring annuloplasty for functional tricuspid regurgitation51.  They demonstrated a 
significant decrease in the recurrence of tricuspid regurgitation in those patients receiving a 
ring annuloplasty and conclude that the ring annuloplasty is the superior form of treatment 
for patients with functional tricuspid regurgitation. 
The issue of whether tricuspid valve repair with an annuloplasty ring leads to an improved 
outcome over a conventional suture annuloplasty repair was addressed by Khorsandi and 
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co-workers in a review of 306 papers in the literature, of which 14 presented the best 
evidence to derive an answer52.  They concluded that most studies supported the use of a 
ring annuloplasty over a suture annuloplasty. 
 
VALVE CHOICE IN TRICUSPID VALVE REPLACEMENT 
It is uniformly accepted that prosthetic valve replacement in the tricuspid position is 
challenged by similar complications documented in the mitral and aortic position.  The 
incidence of thrombo-embolic and thrombotic complications with mechanical prostheses is 
of concern, whilst the problem of structural valve degeneration becomes relevant with 
bioprostheses.  Although partial or total replacement of the tricuspid valve using 
homografts has been reported38, their results remain inconclusive8. 
Kaplan and others debate the selection of the most suitable tricuspid prosthesis in their 
paper describing 129 tricuspid valve replacements over a 20 year period53.  In a cohort 
where the mean age was 35.27 years, 97 patients received a mechanical prosthesis.  They 
found that there was no statistically significant difference between the two recipient groups 
with respect to early mortality, re-replacement and mid-term mortality.  However, their 
preference for a mechanical prosthesis was based on favourable haemodynamic 
characteristics and durability.   
The early and late results of 60 patients who underwent tricuspid valve replacement were 
published by Scully and others after a mean follow-up of 75 months54.  Bioprostheses were 
implanted in 47% of patients and 53% underwent mechanical valve replacement.  The 
hospital morbidity and mortality were not significantly different between the recipient 
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groups.  A late overall mortality of 32% was reported but no difference in survival or valve-
related complications was documented between the mechanical and bioprosthetic groups.  
Their recommendation was for the implantation of a mechanical prosthesis in the tricuspid 
position in younger patients and also in patients receiving mechanical valves in the mitral or 
aortic position who require long-term anticoagulation therapy. 
In a review of 146 consecutive patients who underwent tricuspid valve replacement over a 
25 year period, Van Nooten and co-workers analysed early and late events after a mean 
follow-up of 92 months55.  They reported 70 late deaths with an actuarial survival rate of 
74% at 60 months and 25% at 14 years.  Univariate analysis indicated that the incremental 
risk factors for late death were the type of tricuspid prosthesis used, the type of 
intraoperative myocardial preservation employed as well as the preoperative functional 
class.  They conclude that considering the high operative risk and poor long-term survival 
associated with tricuspid valve replacement, a large-dimension bioprosthesis is preferred 
due to its good initial durability and low risk of valve-related events.  However, a bileaflet 
mechanical valve is proposed in patients with better life expectancy. 
 
DURABILITY AND RISK FACTORS FOR FAILURE 
The fact that recurrent significant tricuspid regurgitation is reported consistently after repair 
of functional tricuspid regurgitation is a marker of the variable durability of current repair 
techniques reported in the literature.   
An evaluation of the durability of different techniques of tricuspid valve repair was 
performed by Sales et al in order to analyse the risk factors for failure of repair56.  They 
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demonstrated inferior durability of repair with suture annuloplasty and pericardial 
techniques.  
McCarthy et al compared the durability of 4 different techniques of tricuspid annuloplasty in 
790 patients undergoing surgery for functional tricuspid regurgitation57.  Residual tricuspid 
regurgitation was reported in 14% of patients early after surgery for all types of 
annuloplasty.  It was found that the severity of preoperative tricuspid regurgitation 
determined the risk of repair failure within the first 6 months.  However, most indicators of 
poor durability appeared to be related to baseline patient characteristics; risk factors 
considered to be irreversible.  Late risk of repair failure was associated not only with 
baseline patient characteristics such as left ventricular dysfunction, but also with avoidable 
factors such as the technique of annuloplasty and the presence of right ventricular pacing 
electrodes. 
Kuwaki et al evaluated independent predictors for early and late unfavourable results in a 
group of 246 patients who underwent tricuspid valve repair for functional tricuspid 
regurgitation by means of either suture or ring annuloplasty58.  The mean duration of 
follow-up was 7.8 years.  The reoperation-free survival rate was 90% at 5 years and 84% at 
10 years.  The severity of preoperative tricuspid regurgitation was found to be a predictor of 
early residual tricuspid regurgitation and increasing severity of residual tricuspid 
regurgitation postoperatively was found to be a risk factor for late tricuspid valve 
reoperation.  
In a 12-year follow-up of 156 patients with combined mitral and tricuspid valve disease who 
underwent mitral and tricuspid valve repair or replacement, Kay et al investigated the long-
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term durability of tricuspid annuloplasty utilizing the bicuspidization technique59.  They 
demonstrated an actuarial survival rate of 57% at 5 years and 44% at 12 years.  Left 
ventricular ejection fraction was found to be the only significant determinant of survival 
after adjustment for age.  The freedom rate from tricuspid valve reoperation at 10 years 
following tricuspid annuloplasty was shown to be 91%.  
In their series of 236 patients undergoing tricuspid valve repair for mild-to-moderate 
functional tricuspid regurgitation in patients with rheumatic mitral valve disease, Kim and 
others published a freedom rate from moderate-to-severe tricuspid regurgitation at 5 years 
of 92.9% in patients undergoing tricuspid repair, versus 60.8% in a control group60. 
A study of 74 patients requiring tricuspid valve reoperation after a previous tricuspid repair 
using either suture or ring annuloplasty was described by Bernal et al after a mean follow-
up of 14.2 years61.  The mean interval between the primary repair and reoperation was 8.2 
years.  Reoperation was indicated because of progression of valve disease in 33.8% of 
patients and for early failure of tricuspid valve repair in 14.9% of patients.   
 
RATIONALE FOR THE STUDY 
Functional tricuspid regurgitation is a relatively common accompaniment in patients with 
mitral and to a lesser extent, aortic valve disease.  Severe tricuspid regurgitation developing 
after successful left-sided heart valve surgery is difficult to manage and is associated with 
poor surgical outcomes and prognosis.  Persistence of tricuspid regurgitation after 
operation for left-sided disease is associated with ongoing symptoms.  This suggests that 
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early detection and appropriate intervention is needed when severe functional tricuspid 
regurgitation is found preoperatively. 
Valvular heart disease of rheumatic aetiology forms a significant portion of the workload at 
the Cardiology and Cardiothoracic Units at Inkosi Albert Luthuli Central Hospital.  Mild-to-
moderate functional tricuspid regurgitation is observed commonly and is considered not to 
require surgical intervention at the time of left-sided valve replacement.  The prevalence of 
severe functional tricuspid regurgitation in patients with clinically significant mitral valve 
disease is common, but is as yet undefined in this population, nor are the sequelae known 
in subjects in whom the tricuspid valve has been repaired.  
This study is designed to study the outcome of patients with severe functional tricuspid 
regurgitation in a rheumatic population undergoing simultaneous tricuspid and left-sided 
















AIMS, MATERIALS & METHODS 
 
Aim 
To evaluate the results of simultaneous tricuspid valve surgery for severe functional 
tricuspid regurgitation in rheumatic heart disease at the time of left-sided valve surgery. 
 
Objectives 
1.     To define the relationship of pulmonary hypertension to long-term outcomes in 
patients with severe tricuspid regurgitation. 
2.      To assess the clinical impact of the development of late severe tricuspid regurgitation 
after successful left-sided valve surgery in terms of congestive heart failure requiring 
hospital admission, repeat tricuspid valve surgery and cardiovascular death (primary end-
point). 
3.      To establish other factors associated with the development of major adverse 
cardiovascular events as well as the occurrence of late severe tricuspid regurgitation 
(secondary end-point) after successful left-sided valve surgery.  
4.      To assess the outcome of tricuspid valve surgery for functional tricuspid regurgitation 






Hypothesis to be tested 
Pulmonary hypertension is associated with persistence and exacerbation of tricuspid 
regurgitation even after successful left-sided valve surgery in rheumatic heart disease. 
Summary of the proposed research 
This study is designed to study the outcome of patients with severe functional tricuspid 
regurgitation undergoing simultaneous tricuspid valve surgery and left-sided valve 
repair/replacement for rheumatic valvular disease.   
 
Materials and methods 
A retrospective analysis of the perioperative and follow-up data of patients who underwent 
tricuspid valve surgery with concomitant mitral and/or aortic valve replacement between July 
2003 and December 2011 at Inkosi Albert Luthuli Central Hospital, Durban, South Africa, 
was undertaken.  
The study was given full ethics approval by the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal on 16 October 2012. 
The records of all patients who were submitted to tricuspid valve replacement or repair for 
severe functional tricuspid regurgitation together with replacement of rheumatic mitral 
and/or aortic valves were analysed, including those patients who had undergone previous 
tricuspid valve repair or replacement and/or previous aortic/mitral valve repair or 
replacement.  Exclusion criteria were patients with congenital heart disease, those 
undergoing additional concomitant cardiac surgical procedures and left-sided valvular 
disease of non-rheumatic aetiology.   
43 
 
All patients were evaluated preoperatively by a combined Cardiology and Cardiothoracic 
Surgery service and submitted for surgery.  The appraisal routinely consisted of a clinical 
evaluation, 12-lead electrocardiogram, chest radiograph, two-dimensional transthoracic 
echocardiogram and baseline haematological and biochemical investigations.   
Patients referred for valve replacement surgery of left-sided lesions who had clinically and   
echocardiographically documented severe tricuspid regurgitation despite optimal medical 
therapy, in association with a dilated tricuspid annulus (end-diastolic diameter >32mm in 
adults), were submitted for combined valvular procedures (mitral and/or aortic valve 
replacement with simultaneous tricuspid valve repair or replacement).   Surgery was 
performed after optimal pre-operative diuretic therapy to reduce congestive symptoms 
whenever the clinical condition of the patient permitted.  Echocardiographic parameters 
recorded both pre- and postoperatively were:  right atrial and ventricular diameter, left 
ventricular dimensions, tricuspid annular diameter, tricuspid valvular morphology, tricuspid 
leaflet mobility, tricuspid valve gradient, the presence of organic disease of the tricuspid 
valve and pulmonary artery systolic pressure.   
Surgery was conventionally performed via median sternotomy with total cardiopulmonary 
bypass using ascending aortic and bicaval venous cannulation utilising moderate 
hypothermia and cold crystalloid cardioplegic arrest.  Where applicable, left-sided 
procedures were completed first, followed by cardiac de-aeration and release of the aortic 
cross-clamp.  Exposure of the tricuspid valve was either via a transverse or oblique right 
atriotomy facilitated by right atrial isolation and performed on the perfused, beating heart 
during rewarming.  Routine intraoperative transoesophageal echocardiography was not 
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employed in this study.  Surgical intervention for atrial fibrillation was not performed in this 
study population either.  The technique of tricuspid repair and selection of replacement 
prostheses were at the discretion of the surgeon.   
The preoperative demographics and clinical characteristics were extracted from inpatient 
records and comprised age, gender, primary valvular pathology, previous surgery, type of 
prosthesis implanted, type of tricuspid valve procedure and echocardiographic parameters 
(end-diastolic dimension, end-systolic dimension, ejection fraction, pulmonary artery 
systolic pressure, degree of tricuspid regurgitation, tricuspid annular dimension, tricuspid 
valve anatomy, tricuspid valve gradient, right ventricular dilatation and right atrial 
dilatation).   
Two-dimensional transthoracic echocardiography and Doppler colour-flow estimation were 
performed using the Acuson Sequoia SC2000 ultrasound device (Siemens AG, Germany).  
Quantification of tricuspid regurgitation was facilitated by the apical four-chamber view and 
classified as mild, moderate or severe when the distal jet area was <5cm2, 5-10cm2 or 
>10cm2 respectively.  
In addition, the immediate echocardiographic outcome at 1 week was documented with 
respect to ejection fraction, pulmonary artery systolic pressure and degree of residual 
tricuspid regurgitation. 
Standard anticoagulation regimens using coumadin-based therapy (warfarin) were used to 
achieve a target international normalised ratio (INR) of 2.0-4.0 where mechanical prostheses 
were implanted.   
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Outcomes were analysed by evaluating data from inpatient records and outpatient follow-up 
visits at 6 weeks, 6 months, 1 year and 2 years postoperatively comprising:  NYHA 
functional class, diuretic therapy and echocardiographic parameters (end-diastolic 
dimension, end-systolic dimension, ejection fraction, pulmonary artery systolic pressure, 
degree of tricuspid regurgitation, tricuspid annular dimension, tricuspid valve gradient, right 
ventricular dilatation, right atrial dilatation and persistent tricuspid regurgitation/gradient 
across the tricuspid valve at last follow-up).  In addition, telephonic follow-up was 
conducted after data capture in order to account for missing follow-up data.  Data was not 
censored for death.   
A significant tricuspid transvalvular gradient was defined as a gradient >2.0mm Hg.  
Prolonged ventilation was defined as mechanical ventilation for greater than 10 days.  
Prolonged intensive care unit stay was defined as an intensive care unit stay greater than 14 
days.  Prolonged hospital stay was defined as an inpatient stay greater than 30 days.    Early 
mortality was defined as death during hospitalisation or within 30 days of surgery.  The 
primary end-point was defined by the occurrence of any of the following major adverse 
cardiovascular events:  death from a cardiovascular cause, the need for tricuspid valve 
reoperation or the presence of postoperative congestive cardiac failure requiring hospital 
admission.  The secondary end-point was defined by the persistence of severe residual 
postoperative tricuspid regurgitation. 
A satisfactory outcome was defined at 2-year follow-up by a combination of:  postoperative 
reduction in diuretic dose, the clinical absence of right heart failure and echocardiographic 
documentation of no more than mild-to-moderate residual postoperative tricuspid 
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regurgitation.  An unsatisfactory outcome was defined when either the primary or secondary 
end-points were recorded. 
Descriptive statistics were the primary focus of this analysis. Numeric data were presented 
by the following descriptive statistics as most appropriate: mean, median, standard 
deviation, range, quartile 1, quartile 3 and interquartile range. Categorical data were 
presented by frequency tables (count and percentage).   
Five categorical independent variables (atrial fibrillation, suture annuloplasty, ring 
annuloplasty, persistent postoperative pulmonary hypertension and severe residual 
postoperative tricuspid regurgitation) were assessed for association to the primary end-
point using Pearson’s Chi-Square test.  A p value <0.05 was considered as statistically 
significant. 
Three continuous variables (preoperative left ventricular ejection fraction, preoperative 
pulmonary artery systolic pressure and postoperative tricuspid transvalvular gradient) were 
also assessed for association to the primary end-point using the Independent Samples T-
test.    A p value <0.05 was considered as statistically significant. 
In order to establish other factors associated with the development of the secondary end-
point, Pearson’s Chi-Square test was applied to 4 categorical independent variables (atrial 
fibrillation, suture annuloplasty, ring annuloplasty, and persistent postoperative pulmonary 




The Independent Samples T-test was used to investigate the relationship between each of 4 
continuous variables (preoperative left ventricular ejection fraction, preoperative pulmonary 
artery systolic pressure and preoperative as well as the postoperative forward tricuspid 
transvalvular gradient) and the secondary end-point.  A p value <0.05 was considered as 
statistically significant. 
Exploratory inferential statistics such as Pearson’s Chi-Square test, Paired-Samples T-test, 
Independent-Samples T-test, Kruskal-Wallis one-way analysis of variance or Wilcoxon 
signed-rank test were used to assess the association between variables.   
SPSS version 21 (SPSS Inc., Chicago, Illinois) was used to analyse the data.  A p value <0.05 



















A total of 30 operations were performed in 30 patients between July 2003 and December 
2011.  The median age was 32.5 years.  The majority of subjects (96.6%) were in New York 
Heart Association (NYHA) functional classes 3 and 4.  The underlying aetiology was 
rheumatic heart disease in the entire study population.  Five patients had undergone prior 
open surgical procedures for left-sided valvular heart disease.  Refer to Table 1. 
Table 1.  Demographic profile (30 patients). 
Age, years    median 32.5, IQR 32.0 
Gender, n (%)    male=8 (26.7) 
NYHA functional class, n (%) 
 Class 1    0 (0.0) 
 Class 2    1 (3.3) 
Class 3    16 (53.3) 
Class 4    13 (43.3) 
Rheumatic aetiology, n (%)   30 (100.0) 
Atrial fibrillation/flutter, n (%)  14 (46.7) 
Previous valve surgery, n (%)  5 (16.7) 
Co-morbidity, n (%) 
 Hypertension   4 (13.3) 
 Previous stroke   2 (6.7) 
  









All subjects had severe tricuspid regurgitation preoperatively secondary to left-sided 
valvular heart disease.  Twenty-six subjects (86.7%) had mitral valve disease.  The 
preoperative characterisation of tricuspid valve leaflet anatomy demonstrated normal 
leaflets in 19 patients (63.3%) and mixed-tricuspid valve disease in 11 patients (36.7%).  The 
pulmonary artery systolic pressure was elevated in all subjects.  The mean tricuspid annular 
diameter was 37.3±6.3mm.  Nine subjects (30%) were identified preoperatively to have a 
forward gradient >2.0mm Hg across the tricuspid valve.  The median left ventricular 
ejection fraction was 55.0% (interquartile range 15.0%).  Twenty subjects (66.7%) had a left 
ventricular ejection fraction between 40 and 59%.   In this subgroup 13 patients (65.0%) had 
mitral valve disease, of whom 5 had mitral stenosis (38.4%) and 2 had mitral regurgitation 
















Table 2.  Preoperative echocardiographic data (30 patients). 
 Left-sided valve pathology, n (%) 
  Mixed-mitral valve disease    9   (30.0) 
  Predominant stenosis   5   (16.7) 
               Predominant regurgitation   4   (13.3) 
  Mitral stenosis     10 (33.3) 
  Mitral regurgitation    7   (23.3) 
  Aortic stenosis     1   (3.3) 
  Aortic regurgitation    3   (10.0) 
Tricuspid valve anatomy, n (%) 
 Normal leaflets     19 (63.3) 
 Mixed-tricuspid valve disease   11 (36.7) 
Dilated right atrium, n (%)     30 (100.0) 
Dilated right ventricle, n (%)    30 (100.0) 
Median pulmonary artery systolic pressure, mm Hg  64.0, IQR 30.0 
Pulmonary artery systolic pressure, n (%) 
 30-39 mm Hg     0    (0.0) 
 40-59 mm Hg     12 (40.0) 
 >60 mm Hg     18 (60.0) 
Tricuspid valve annular diameter, n (%) 
 32-35mm     14 (46.7) 
 36-39mm     7   (23.3) 
 >40mm      9   (30.0) 
Tricuspid valve gradient >2.0mm Hg, n (%)   9   (30.0) 
Mean tricuspid valve annular diameter, mm   37.3±6.3 
Mean left ventricular end diastolic dimension, mm  55.2±11.5 
Mean left ventricular end systolic dimension, mm  40.0±9.5 
Median left ventricular ejection fraction, %   55.0, IQR 15.0 
Left ventricular ejection fraction, n (%)  
 >60%      9   (30.0) 
 50-59%      11 (36.7) 
 40-49%      9   (30.0) 
 <20%      1   (3.3) 






All subjects had left-sided valve replacement as well as concomitant tricuspid valve 
procedures.   
A total of 23 mitral valve replacements were performed.   In addition, there was 1 aortic 
valve replacement, 4 double-valve replacements and 2 redo mitral valve replacement 
operations.  Mechanical valves were implanted in 26 of the study patients (86.7%).  The 
mechanical prostheses used comprised the Sorin Bicarbon (Sorin Biomedica, Saluggia, Italy), 
On-X (MCRI, Austin, Texas), Medtronic Advantage (Medtronic Inc, Minneapolis, Minnesota)  
and St Jude Regent valves (St Jude Medical Inc, St Paul, Minnesota).  Bioprosthetic valve 
replacements were performed using the Medtronic Hancock 2 (Medtronic Inc, Minneapolis, 
Minnesota) and Carpentier-Edwards Perimount valves (Edwards Lifesciences, Irvine, 
California).  Refer to Table 3. 
Table 3.  Distribution of implanted valve prostheses by left-sided procedure. 
     MVR  AVR  DVR  redo MVR 
Mechanical valves, n 
Sorin Bicarbon   1    1 
On-X    16  1  1  2 
Medtronic Advantage  2 
St Jude Regent   1    1 
Bioprosthetic valves, n 
Medtronic Hancock 2  2    1 
Carpentier-Edwards Perimount 1 





With respect to simultaneous tricuspid valve procedures, tricuspid valve repair was 
performed in 28 patients (93.3%). The remaining 2 patients underwent tricuspid valve 
replacement.  Twenty-two subjects (73.3%) had a suture annuloplasty procedure (De Vega) 
and a ring annuloplasty was employed in 6 subjects (20.0%).  In the latter group, the devices 
implanted were the Duran Ancore ring (Medtronic Inc, Minneapolis, Minnesota), the 
Carpentier-Edwards ring (Edwards Lifesciences, Irvine, California) and the Carbomedics ring 
(Sulzer Carbomedics, Austin, Texas).  Medtronic Hancock 2 bioprostheses were implanted in 




















Table 4.  Surgical procedures (30 patients). 
Previous left-sided valve surgery, n (%) 
 Mitral valve repair    1 (3.3) 
 Mitral valve replacement   3 (10.0) 
 Aortic valve replacement   1 (3.3) 
Composite procedures, n (%) 
 MVR, tricuspid suture annuloplasty  16 (53.3) 
 MVR, tricuspid ring annuloplasty   5 (16.7) 
 MVR, TVR    2 (6.7) 
 Redo MVR, tricuspid suture annuloplasty  2 (6.7) 
 DVR, tricuspid suture annuloplasty  3 (10.0) 
 DVR, tricuspid ring annuloplasty  1 (3.3) 
 AVR, tricuspid suture annuloplasty  1 (3.3) 
Type of left-sided prosthesis used, n (%) 
 Mechanical 
  MVR    20 (66.7) 
  DVR    4 (13.3) 
  Redo MVR   2 (6.7) 
 Biological  
  MVR    3 (10.0) 
  DVR    1 (3.3) 
Type of tricuspid valve procedure, n (%) 
 Tricuspid valve repair 
 Suture annuloplasty  22 (73.3) 
  Ring annuloplasty   6 (20.0) 
 Tricuspid valve replacement 
  Bioprosthetic   2 (6.7) 
Type of tricuspid device used, n (%) 
 Annuloplasty ring 
  Carpentier-Edwards ring  2 (6.7) 
  Carbomedics ring   1 (3.3) 
  Duran ring   3 (10.0) 
 Prosthetic valve  
  Medtronic Hancock 2   2 (6.7) 
Abbreviations:  MVR, mitral valve replacement; AVR, aortic valve replacement;  DVR, mitral and aortic valve 






There were 2 early deaths from cardiovascular causes in the study.  One patient had 
intractable heart failure postoperatively resulting in a prolonged intensive care stay and  
demised on day 30.  The immediate postoperative echocardiogram demonstrated an 
ejection fraction of 20% (preoperative ejection fraction 58%) with severe residual tricuspid 
regurgitation.  The second patient exhibited a low cardiac output state immediately 
postoperatively and demised on day 2 prior to postoperative echocardiographic evaluation.  
The preoperative echocardiogram demonstrated normal tricuspid leaflet anatomy without a 
transvalvular gradient, an ejection fraction of 45%, a pulmonary artery systolic pressure of 
45mm Hg and a tricuspid annular diameter of 39mm.  
Left ventricular dysfunction was documented in 3 additional patients postoperatively.  Refer 










Table 5.  Echocardiographic and bypass parameters recorded for 5 patients with 
















Severe MR 44 60 60 30 46 Discharged 
day 23 
Severe MR 84 71 55 30 67 Discharged 
day 21 
Severe MR 41 69 58 
 
20 48 Demised 
Moderate MS, 
severe AR 





45 60 45 Not recorded 146 Demised  
Abbreviations:  EF, ejection fraction;  EDD, end-diastolic dimension;  PAS, pulmonary artery systolic pressure;  MR, 
mitral regurgitation;  MS, mitral stenosis;  AR, aortic regurgitation. 
 
Right heart failure was noted in 11 patients.  Three of these patients had a preoperative 
tricuspid transvalvular gradient which was noted to resolve postoperatively.  In 2 other 
patients without a preoperative transvalvular gradient, a postoperative transvalvular gradient 
was a new finding.  Half the subjects with right heart failure postoperatively (54.5%) had a 
preoperative pulmonary artery systolic pressure of between 50-69mm Hg.  In addition, half 
the subjects (54.5%) from the same subgroup had a preoperative tricuspid annular diameter 
between 32-35mm.  Using the Independent Samples T-test, none of the following 
preoperative variables (tricuspid valve gradient, pulmonary artery systolic pressure and 
tricuspid annular diameter) were found to be statistically significant factors for the 
development of postoperative right heart failure.   
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One patient with a low preoperative ejection fraction (15%) demonstrated a postoperative 
ejection fraction of 35% with mild residual tricuspid regurgitation following aortic valve 
replacement and tricuspid suture annuloplasty.  He had a prolonged hospital stay (74 days)  
due to cardiac failure and was in functional NYHA class 2 on discharge. 
There were 2 subjects with a preoperative pulmonary artery systolic pressure >110mm Hg.  
One patient with a pulmonary artery systolic pressure of 113mm Hg underwent a mitral 
valve replacement and tricuspid suture annuloplasty resulting in moderate postoperative 
tricuspid regurgitation with a pulmonary artery systolic pressure of 57mm Hg and a left 
ventricular ejection fraction of 65%.  He was in NYHA functional Class 3 when discharged on 
day 7.  The patient with a pulmonary artery systolic pressure of 126mm Hg underwent a 
mitral valve replacement and tricuspid ring annuloplasty and demonstrated mild 
postoperative tricuspid regurgitation with a pulmonary artery systolic pressure of 64mm Hg 
and a left ventricular ejection fraction of 35%.  He was in NYHA functional class 2 when 
discharged on day 79. 
 
Intermediate Outcomes 
At 6 weeks postoperatively, a forward gradient >2.0mm Hg was recorded across the 
tricuspid valve in 2 patients and in 2 patients a tricuspid valvular periprosthetic leak was 
observed.  Of the 2 patients with a transvalvular gradient, 1 had an identifiable gradient 
preoperatively whilst 1 had a new gradient identified after tricuspid suture annuloplasty.   
Three patients had a period of prolonged ventilation (>10 days) postoperatively.  Four 
patients had a prolonged intensive care unit stay (>14 days) postoperatively.  Thirteen 
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patients had a prolonged hospital stay (>30days) postoperatively.  The median hospital stay 
was 23.0 days (interquartile range 29.0 days).   
Other complications identified were deep sternal wound sepsis in 1 patient and pressure 
ulcers in 3 patients.  Refer to Table 6. 
Table 6.  Operative outcomes. 
Immediate outcomes, n (%) 
 Early mortality     2 (6.6) 
 Left ventricular dysfunction    3 (10.0) 
 Cardiac  failure     11 (36.7) 
Intermediate outcomes, n (%) 
 Residual TR at 6 weeks 
  None     1 (3.3) 
  Mild      11 (36.7) 
  Moderate     5 (16.7) 
  Severe      8 (26.7) 
Tricuspid valve gradient >2.0mm Hg at 6 weeks 2 (6.6) 
Prolonged ventilation    3 (10.0) 
 Prolonged ICU stay    4 (1.3) 
Deep sternal wound sepsis    1 (3.3) 
Pressure ulcers     3 (10.0) 
Prolonged hospital stay     13 (43.3) 
Delayed outcomes, n (%) 
Primary end-point reached 
  Cardiovascular death   6 (20.0) 
  Readmission for cardiac failure  4 (1.3) 
  Tricuspid valve reoperation   0 (0.0) 
Secondary end-point reached 
  Severe residual tricuspid regurgitation 8 (26.7) 





A statistically significant improvement (p<0.001) in NYHA functional class was documented 
in 24 subjects (80%) between the preoperative and 6-week postoperative NYHA functional 
class using the Wilcoxon signed-rank test.   Descriptive analysis of NYHA functional class is 
represented in Table 7.  
Table 7.   Comparison of immediate outcomes at 6 weeks (27 patients) with baseline data 
(30 patients). 
            Preoperative, n (%)  Postoperative, n (%)  p Value  
NYHA Class 1     0 (0.0)  7 (23.3)   NA 
                             
NYHA Class 2                      1 (3.3)  8 (26.7)   NA 
                                     
NYHA Class 3               16 (53.3) 10 (33.3)  NA      
                                  
NYHA Class 4                        13 (43.3) 2 (6.7)   NA 
 
Mean tricuspid annular diameter, mm  37.3±6.3 30.8±5.5  0.001 
Mean pulmonary artery systolic pressure, mm Hg 67.0±21.6 49.7±12.1  0.001 
Severe tricuspid regurgitation, n (%)   30 (100.0) 8 (26.7)   <0.001 
Mean left ventricular ejection fraction, %  53.7±11.0 41.7±15.1  0.004 
Abbreviations: NYHA, New York Heart Association;  NA, not applicable. 
 
The immediate echocardiographic outcome at 6 weeks was studied with respect to tricuspid 
annular diameter, transvalvular gradient, left ventricular ejection fraction, pulmonary artery 
systolic pressure and the presence of severe tricuspid regurgitation and compared to the 
preoperative data using the Paired-Samples T-test.  There were significant reductions in the 
postoperative tricuspid annular diameter, pulmonary artery systolic pressure, incidence of 
severe tricuspid regurgitation and tricuspid transvalvular gradient.  However, a significant 





The postoperative echocardiographic data at 1 year are presented in Table 8. 
Table 8.  Postoperative echocardiographic data at 1 year (21 patients). 
 
Mean pulmonary artery systolic pressure, mm Hg    42.0±10.9 
Pulmonary artery systolic pressure, n (%) 
 <30mm Hg      3   (10.0) 
               30-39 mm Hg      7   (23.3) 
 40-59 mm Hg      10 (33.3) 
 >60 mm Hg      0   (0.0) 
Mean tricuspid valve annular diameter, mm    33.7±4.6 
Median tricuspid valve gradient >2.0mm Hg, n (%)   1.9,   IQR 3.4 
Median left ventricular end diastolic dimension, mm   52.2, IQR 8.0 
Median left ventricular end systolic dimension, mm   37.0, IQR 3.0 
Median left ventricular ejection fraction, %    46.0, IQR 15.0 
Left ventricular ejection fraction, n (%)  
 >60%       2 
 50-59%       6  
 40-49%       9 
 30-39%          1 
 20-29%       2   




The primary end-point was recorded in 10 patients (33.3%) at completion of the follow-up 
period comprising cardiovascular death (6 patients) and readmission for cardiac failure (4 
patients).  Tricuspid valve reoperation was not performed in this group during the study 
period. 
In order to establish other factors associated with the development of the primary end-
point, Pearson’s Chi-Square test was applied to 5 categorical independent variables (atrial 
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fibrillation, suture annuloplasty, ring annuloplasty, persistent postoperative pulmonary 
hypertension and severe residual postoperative tricuspid regurgitation) with respect to the 
primary end-point.  Persistent postoperative pulmonary hypertension was found to be the 
only statistically significant independent variable (p<0.002) associated with the primary 
end-point. 
The Independent Samples T-test was used to investigate the relationship between each of 3 
continuous variables (preoperative left ventricular ejection fraction, preoperative pulmonary 
artery systolic pressure and postoperative tricuspid transvalvular gradient) and the primary 
end-point.  Only the preoperative pulmonary artery systolic pressure was found to have a 
statistically significant impact on the primary end-point (p 0.013). 
 
Secondary End-point 
The secondary end-point of severe residual postoperative tricuspid regurgitation was 
reached in 8 patients (26.7%) at completion of the follow-up period.  Three of these patients 
had a forward transvalvular gradient >2.0mm Hg documented preoperatively. The 
relationship of the secondary end-point on the primary end-point was investigated by 
Pearson’s Chi-Square test and found not to be statistically significant (p 0.149). 
In addition, the effect of the severity of residual postoperative tricuspid regurgitation on the 
primary end-point was investigated using the Kruskal-Wallis one-way analysis of variance.  
No significant difference was observed amongst the 3 categories of residual postoperative 




Table 9.  Frequencies and percentages for variables assessed for association with the 
primary and secondary end-points. 
 
 sample 
Valid Missing Total 
n % n % n % 
primary end point * AF 30 100.0% 0 0.0% 30 100.0% 
primary end point * SA 30 100.0% 0 0.0% 30 100.0% 
primary end point * SRTR 27 90.0% 3 10.0% 30 100.0% 
primary end point * RA 30 100.0% 0 0.0% 30 100.0% 
primary end point * 
severe TR 
30 100.0% 0 0.0% 30 100.0% 
 













secondary endpoint * SA 30 100.0% 0 0.0% 30 100.0% 
secondary endpoint * 
SRTR 
27 90.0% 3 10.0% 30 100.0% 
secondary endpoint * RA 30 100.0% 0 0.0% 30 100.0% 
secondary endpoint * 
severe TR 
30 100.0% 0 0.0% 30 100.0% 
 
Abbreviations:  AF, fibrillation; SA, suture annuloplasty; SRTR, severe residual postoperative tricuspid regurgitation; 
RA, ring annuloplasty; TR, tricuspid regurgitation. 
 
 
Persistence of severe postoperative tricuspid regurgitation 
By use of the Independent Samples T-test, neither of the following preoperative categorical 
variables (pulmonary artery systolic pressure and tricuspid annular diameter) was found to 
have an impact on severe persistent postoperative tricuspid regurgitation.  In addition, no 
association between the preoperative tricuspid leaflet anatomy and severe persistent 
postoperative tricuspid regurgitation was demonstrated using Pearson’s Chi-square test. 
In order to establish other factors associated with the development of the secondary end-
point, Pearson’s Chi-Square test was applied to 4 categorical independent variables (atrial 
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fibrillation, suture annuloplasty, ring annuloplasty, and persistent postoperative pulmonary 
hypertension) with respect to the secondary end-point.  None of the listed variables were 
statistically significant.  
The Independent Samples T-test was used to investigate the relationship between each of 4 
continuous variables (preoperative left ventricular ejection fraction, preoperative pulmonary 
artery systolic pressure and preoperative as well as the postoperative forward tricuspid 
transvalvular gradient) and the secondary end-point.  None of these variables were 
statistically significant with respect to the secondary end-point. 
 
Ring annuloplasty vs suture annuloplasty on primary and secondary end-points 
Using Pearson’s Chi-Square Test, the association between the technique of annuloplasty and 
the primary and secondary end-points was investigated.  Neither of the tricuspid repair 
techniques impacted on the primary or secondary end-points. 
                                                                                                                                            
Outcome of tricuspid valve surgery in patients undergoing left-sided valve surgery 
Analysis of surgical outcomes at 2 years as defined by the study protocol demonstrated a 
satisfactory outcome in 12 patients (40.0%) and an unsatisfactory outcome in 10 patients 
(33.3%).  The remaining 8 patients were lost to follow-up. 
 
Relationship between pulmonary hypertension and long-term surgical outcomes 
The relationship between postoperative pulmonary hypertension and long-term outcomes in 
patients with surgically treated severe tricuspid regurgitation was examined using Pearson’s 
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Chi-Square test in relation to the primary and secondary end-points.  The presence of 
persistent postoperative pulmonary hypertension was found to be a statistically significant  
risk factor (p<0.02) for major adverse cardiovascular events (primary end-point).  However, 
the presence of persistent postoperative pulmonary hypertension was not statistically 
significant with respect to the occurrence of severe residual postoperative tricuspid 
regurgitation (secondary end-point). 
 
Follow-up 
The median follow-up duration was 544.0 days (interquartile range 1357.0 days).  Follow-
up was complete in 16 patients (53.3%) and 8 patients (26.7%) were lost to follow-up (range 
0-113 days).   
There were 4 late deaths reported during follow-up excluding the 2 reported in-hospital 
deaths.   One was due to a clotted mechanical mitral valve.  In addition, 1 patient had a 
cerebrovascular accident, the mechanism of which was not established, and in whom the 
adequacy of anticoagulation was unknown.   
Table 10 summarises the number of patients available for analysis at prescribed time-







Table 10.  Analysis of follow-up at prescribed study intervals. 
Follow-up 
interval  
Total number of 
patients lost to 
follow-up 
Total number of 
patients demised 
Comments 
6 weeks 2 
 
2 2 in-hospital deaths 
6 months 5 
 
2 5 patients untraceable at 6 months 
1 year 6 
 
3 1 further death at 1 year, cause of death unknown but 
left ventricular dysfunction documented 
2 years 8 
 
6 3 further late deaths;  cause of death:  stroke, clotted 
mechanical valve and unknown  
3 further patients untraceable at 2 years 
 
Analysis of the diuretic dose at 2-year follow-up demonstrated an increased dose in 2 
patients (6.7%), a decreased dose in 8 patients (26.7%) and an unchanged dose in 6 patients 
(20.0%).   
A persistent forward transvalvular gradient >2.0mm Hg was observed in 4 patients (13.3%) 
at 2-year follow-up.  The mean transvalvular gradient for the corresponding period was 
3.8±2.16mm Hg.  Of the original 9 patients with a preoperatively detectable gradient, 2 
patients had a persistent gradient at 2 years postoperatively (numbers 1 & 2, Table 11) and 
the gradient was abolished in 6 patients.  Furthermore, a postoperative gradient at 2 years 





Table 11.  Clinical and echocardiographic characteristics of subjects with residual 
postoperative tricuspid transvalvular gradients at 2-year follow-up. 














1 2.6 2 Decreased  Severe  38 Normal 
leaflets 
2 3.0 2 Increased  Severe   48 Normal 
leaflets 
3 5.3 1 Decreased  Severe  57 Fusion of 
anterior and 
septal leaflets 
4 5.9 2 Decreased Mild  55 Mildly 
thickened 
leaflets 
Abbreviations:  TV, tricuspid valve;  NYHA, New York Heart Association; TR, tricuspid regurgitation;  PAS, pulmonary 

















  CHAPTER 5 
DISCUSSION 
 
This study shows that whilst the early results of surgery for functional tricuspid 
regurgitation are encouraging, there was a high prevalence (26.7%) of severe residual 
postoperative tricuspid regurgitation contributing to poor long-term outcomes. 
Significantly, the study disproved the hypothesis that postoperative pulmonary hypertension 
is the major cause of persistence and exacerbation of tricuspid regurgitation even after 
successful left-sided valve surgery.  We have shown that severe residual postoperative 
tricuspid regurgitation was not due to the presence of persistent postoperative pulmonary 
hypertension alone, but may be explained by several other factors.  This finding is 
consistent with that of Matsuyama and colleagues who sought to identify predictors of 
residual tricuspid regurgitation after mitral valve surgery24.  They suggest that several 
mechanisms may be responsible for the high prevalence of late tricuspid regurgitation 
including persistent pressure overload from pulmonary hypertension, right ventricular 
dysfunction, tricuspid annular dilatation and a postoperative increase in cardiac output 
which may inhibit the regression of tricuspid annular dilatation.   
The major findings of this study may be summarised as follows:  A statistically significant 
improvement in NYHA functional class was documented between the preoperative and 6-
week postoperative exercise capacity.  There was a significant reduction at 6 weeks in the 
postoperative tricuspid annular diameter, pulmonary artery systolic pressure, tricuspid 
regurgitation severity and tricuspid transvalvular gradient.  In addition, there was a 
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significant deterioration in the postoperative ejection fraction.  The primary end-point 
(death from a cardiovascular cause/the need for tricuspid valve reoperation/the presence of 
postoperative congestive cardiac failure requiring hospital admission) was recorded in 10 
patients (33.3%) at completion of follow-up.  Both, preoperative and persistent 
postoperative pulmonary hypertension were found to be statistically significant variables 
with respect to major adverse cardiovascular events (primary end-point).  The secondary 
end-point (severe residual postoperative tricuspid regurgitation) was reached in 8 patients 
(26.7%) at completion of follow-up.  There was no association between the secondary end-
point and the development of major adverse cardiovascular events (primary end-point). 
A further important finding of this study was that we found co-existent mixed-tricuspid 
valve disease in 36.7% of subjects.  This is not surprising since this study population 
consisted of predominantly young patients with rheumatic valvular disease.  The 
significance of this aetiology is that there is potential for organic tricuspid valve disease to 
be present preoperatively in the form of rheumatic involvement of the leaflets or 
commissures.  This is highlighted by the development of a new postoperative gradient in 2 
patients in the study sample.  Of note is that the classical markers for organic valve disease 
(leaflet thickening, fusion, tethering, stiffness and failure of coaptation) may not always be 
discernible using conventional two-dimensional transthoracic echocardiography12.  This 
idea is further explored by Henien and others, who contend that in patients with rheumatic 
mitral valve disease, organic tricuspid valve involvement is commoner than what may be 
apparent on routine transthoracic echocardiography12.  Therefore, reliance on two-
dimensional transthoracic echocardiography for assessment of valvular morphology may 
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compound the problem of non-recognition of a transvalvular gradient.  In the absence of 
evaluation by three-dimensional echocardiography, it may be possible for organic tricuspid 
disease to remain unrecognised.  The use of two-dimensional transthoracic 
echocardiography therefore represents a potential limitation of this study.   
It may be inferred that in the subgroup with mixed-tricuspid valve disease, the significance 
of the forward transvalvular gradient in the presence of severe tricuspid regurgitation was 
not recognised at the time of surgical decision-making, hence the low rate of tricuspid valve 
replacement and a preference for tricuspid repair procedures.  This serves to emphasise the 
importance of recognising the presence of a tricuspid transvalvular forward gradient, both, 
at initial echocardiographic evaluation as well as during preoperative and intraoperative 
evaluation.  The presumption that the underlying tricuspid pathology is “functional” 
regurgitation carries a potential for non-recognition of organic disease of the tricuspid valve 
with resultant errors in surgical decision-making.  In this context, it should be stated that 
the potential presence of a transvalvular forward gradient should be actively sought after, 
even in the presence what is ostensibly “functional” tricuspid regurgitation.  Routine 
intraoperative use of transoesophageal echocardiography may reduce errors in assessment 
and also enhance the immediate results of tricuspid repair procedures.   
Of greater concern, is the conclusion by Henein and others that rheumatic leaflet 
involvement contributes to severe tricuspid regurgitation occurring long after mitral valve 
surgery12.  An additional concern is raised by Bernal and co-workers who observe that in 
patients with rheumatic valve disease, the durability of tricuspid valve repair is compromised 
by the active and progressive characteristics of the disease process44.    As a consequence, 
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surgical techniques reserved for the management of functional tricuspid regurgitation may 
be erroneously applied to this group of patients who require tricuspid valve replacement 
instead, resulting in unpredictable outcomes.  Bernal and others underscore this point with 
their conclusion that the results of tricuspid valve repair for organic disease are less 
favourable than those of repair procedures for functional tricuspid regurgitation62. 
The fact that almost half the study patients had atrial fibrillation preoperatively is consistent 
with the finding that atrial fibrillation and tricuspid annular dilatation are directly related to 
left atrial dilatation on the basis of increased left atrial pressure5.  However, in our study, 
the presence of atrial fibrillation was shown to have no correlation with severe residual 
postoperative tricuspid regurgitation (secondary end-point) or the primary end-point (death 
from a cardiovascular cause/the need for tricuspid valve reoperation/the presence of 
postoperative congestive cardiac failure requiring hospital admission).  This contrasts with 
other reports where the presence of atrial fibrillation was demonstrated to be a risk factor 
for residual tricuspid regurgitation24,26.  Similarly, Song and co-workers found atrial 
fibrillation to be an independent risk-factor for the development of late severe tricuspid 
regurgitation26.  Fuster et al suggest that routine surgical elimination of atrial fibrillation 
could significantly reduce the incidence of late severe tricuspid regurgitation.  The fact that 
surgical ablation for atrial fibrillation was not performed in this group may represent a 
further shortcoming of this study.  
The distribution of tricuspid valve repair procedures in this study demonstrated a bias 
towards suture annuloplasty (73.3%) versus ring annuloplasty (20.0%).  The choice between 
suture annuloplasty and ring annuloplasty may be possibly explained by a procedure 
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selection bias amongst the participating surgeons.  Potential factors include personal 
preference, previous surgical experience and performance bias.  The suture annuloplasty 
technique is less expensive, simpler to perform and less time consuming but its inherent 
drawback is a lack of reproducibility when exact quantitative repair techniques are not 
employed33,63.  As a result, surgical outcomes with this technique are less predictable.  In 
view of the published superiority of results with ring annuloplasty techniques, it would be 
desirable for the available clinical evidence to prevail over personal preference in the 
selection of tricuspid repair procedures48,49,50,51,52. 
The use of mechanical valves predominated in the left-sided valve replacement procedures, 
but only biological valves were implanted in the tricuspid position in this study population.  
Valve choice is influenced by patient and prosthesis characteristics.  This study sample 
consisted of a relatively young population (median age 32.5 years) similar to the cohort 
described by Kaplan et al wherein mechanical valve choice in the tricuspid position was 
based on favourable haemodynamic characteristics and durability53.  Similarly, Scully and 
others recommend a mechanical prosthesis in the tricuspid position in younger patients also 
receiving mechanical valves on the left-side necessitating anticoagulation therapy54.  The 
use of bioprostheses in the tricuspid position is tempered by concerns over long-term 
durability and thrombogenicity.  The observed preference for a tricuspid bioprosthesis in 
our study population may be explained by concerns over poor compliance with 
anticoagulation therapy and monitoring in this study population, with the attendant risk of 
mechanical tricuspid valve thrombosis. 
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In 36.7% of subjects, right heart failure was documented postoperatively at 6 weeks.  It is 
relevant to note that Guenther and others propose that this patient cohort reflects an 
advanced stage of heart disease often accompanied by severe right ventricular 
dysfunction39.  It may be surmised that postoperative right heart failure may be a continuum 
of preoperative right ventricular dysfunction not immediately remediable by surgical 
intervention in the face of elevated pulmonary artery pressure.  In this study, none of the 
following preoperative variables:  tricuspid valve gradient, pulmonary artery systolic 
pressure and tricuspid annular diameter were found to be causally related to this 
complication.  Possible reasons for this may include the relatively small sample size studied, 
a delayed reduction in pulmonary artery pressure and persistence of right ventricular 
dysfunction. 
Severe residual tricuspid regurgitation occurred in 26.7% of subjects at 6 weeks 
postoperatively.  This figure appears to be unexpectedly high given the anticipation that 
tricuspid regurgitation would regress postoperatively as pulmonary artery pressure 
diminishes.  The fact that the entire subgroup with severe residual tricuspid regurgitation 
underwent tricuspid suture annuloplasty is noteworthy.  The high observed incidence of 
severe postoperative tricuspid regurgitation may possibly be explained by the following: the 
sequelae of rheumatic leaflet disease12, inefficacy of the suture annuloplasty procedure, 
tricuspid repair techniques being applied inappropriately in the presence of mixed-tricuspid 
valve disease, the presence of tricuspid leaflet tethering28 or atrial fibrillation24,26 and 
inadequate preservation of the mitral subvalvar apparatus27. 
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The observation that a statistically significant decline in postoperative left ventricular 
function occurred in this study is remarkable.  Inadequate myocardial preservation may be a 
possible contributing factor.  However the interplay between systolic wall stress and 
myocardial fibre shortening may account for the diminished ejection fraction more 
convincingly.  In decompensated mitral regurgitation, reduced ejection fraction may occur 
as a result of decreased myocardial fibre shortening in response to increased systolic wall 
stress following mitral valve replacement.  In compensated mitral regurgitation, despite a 
reduced afterload following mitral valve replacement, the ejection fraction may diminish due 
to disrupted mitral annular and subvalvar function. 
The high observed incidence of severe residual postoperative tricuspid regurgitation 
highlights the issue of tricuspid repair failure.  McCarthy et al documented a 14% incidence 
of residual tricuspid regurgitation early postoperatively for all types of annuloplasty.  They 
concluded that the severity of preoperative tricuspid regurgitation determined the risk of 
repair failure within the first 6 months of surgery57.  This conclusion is reinforced by Kuwaki 
and others who found that the severity of preoperative tricuspid regurgitation predicted 
early residual tricuspid regurgitation58.  Significantly, severe preoperative functional 
tricuspid regurgitation was an inclusion criterion for this study, therefore the high observed 
incidence of severe residual tricuspid regurgitation may be a self-fulfilling phenomenon 
based on pre-selection.   
Surgical decision-making in the presence of functional tricuspid regurgitation is challenged 
by the uncertainty whether this phenomenon will regress or progress after surgery if left 
untreated.  However, the scientific literature identifies some predictors of residual tricuspid 
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regurgitation after left-sided surgery, the cognisance of which may influence surgical 
strategies.  These factors are:  a left atrial diameter >60mm, atrial fibrillation, preoperative 
tricuspid annular dilatation, age, female gender, rheumatic aetiology, failure to preserve the 
mitral subvalvar apparatus, failure to surgically eliminate atrial fibrillation and preoperative 
tricuspid leaflet tethering24,25,26,27,28.  
In this study, there was no statistical relationship between the presence of severe residual 
postoperative tricuspid regurgitation and the following variables: atrial fibrillation, suture 
annuloplasty, ring annuloplasty, persistent postoperative pulmonary hypertension, left 
ventricular ejection fraction, preoperative pulmonary artery systolic pressure, preoperative 
tricuspid leaflet anatomy, tricuspid annular diameter and postoperative tricuspid 
transvalvular gradient.  This partially contradicts the surgical literature where atrial 
fibrillation24,26 and preoperative tricuspid annular dilatation25 have already been 
demonstrated to be related to the occurrence of residual postoperative tricuspid 
regurgitation.  The relatively small sample size may account for our finding.   
With regard to the primary end-point, which was documented in 33.3% of subjects, the 
absence of tricuspid valve reoperation in this study was significant.  It may be postulated 
that subjects either demised prior to repeat surgery, or that their clinical condition did not 
permit reoperative surgery.  In a series of patients undergoing tricuspid valve reoperation 
after previous tricuspid repair, Bernal et al found that reoperation was indicated in 33.8% of 
patients due to progression of valve disease and in 14.9% of patients for early failure of 
tricuspid valve repair61.  Their high recorded incidence of reoperation may be due to the fact 
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that the reported mean interval between primary repair and reoperation was 8.2 years, a 
time-frame far exceeding the follow-up period in our study.   
In this study, the primary end-point of major adverse cardiovascular events (death from a 
cardiovascular cause/the need for tricuspid valve reoperation/the presence of postoperative 
congestive cardiac failure requiring hospital admission) was found to have no statistical 
association with the following variables: atrial fibrillation, suture annuloplasty, ring 
annuloplasty, preoperative left ventricular ejection fraction, postoperative tricuspid 
transvalvular gradient and severe residual postoperative tricuspid regurgitation.  This 
finding differs from published reports where preoperative left ventricular dysfunction45  and 
non-use of an annuloplasty ring44,48,49 have been shown to be related to major adverse 
cardiovascular events.  However, in this study the preoperative pulmonary artery systolic 
pressure and persistence of postoperative pulmonary hypertension were found to be 
associated with major adverse cardiovascular events; the former being consistent with the 
surgical literature46.   
The relationship between ring annuloplasty and suture annuloplasty on the primary and 
secondary end-points was investigated but neither of these repair techniques made a 
statistically significant impact on the 2 end-points.  It is possible that the small sample size 
may have masked the true influence of suture annuloplasty on the end-points in this study.  
These findings contrast with the surgical literature which indicates that ring annuloplasty is 
the superior form of treatment for patients with functional tricuspid regurgitation48,49,51.  In 
a multivariate analysis, Tang and others showed that the use of an annuloplasty ring was an 
independent predictor of long-term survival48.  They also illustrated better event-free 
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survival, freedom from recurrent tricuspid regurgitation and fewer tricuspid reoperations in 
the ring annuloplasty group.  Guenther and others affirm this with evidence that ring 
annuloplasty is associated with improved survival and a lower reoperation rate49.  
Seitelberger et al report that survival in the suture annuloplasty group was lower during 
long-term follow-up50.  They also found a greater tendency for recurrent tricuspid 
regurgitation as well as a higher rate of tricuspid valve reoperation in the suture 
annuloplasty group.  
Surgical outcomes were analysed by defined criteria described in the study protocol.  A 
satisfactory outcome was demonstrated in only 40% of patients.  A major contributing factor 
to unsatisfactory outcomes was the occurrence of severe residual tricuspid regurgitation at 
long-term follow-up.   We could not make any inferences from this data because of the 
small sample size and the loss of 26.7% of subjects to follow-up.  However, it may be 
postulated that outcomes could be improved by the selection of surgical strategies which 
result in a lower incidence of severe residual postoperative tricuspid regurgitation, namely 
the routine use of preoperative three-dimensional and intraoperative transoesophageal 
echocardiography and wider application of ring annuloplasty repair as well as surgical 
ablation of atrial fibrillation. 
The limitations identified in this study are related to study design.  It is a retrospective, 
observational, non-randomised study with a potential for procedure selection bias.  The 
relatively small sample size was a recognized limitation of this study with respect to 
statistical power.  Also undermining statistical power was the fact that 26.7% of patients 
were lost to follow-up. The use of two-dimensional transthoracic echocardiographic 
76 
 
evaluation, failure to elucidate preoperative tricuspid leaflet tethering and non-use of 
intraoperative transoesophageal echocardiography as well as failure to surgically ablate 
atrial fibrillation may be additional study limitations.  A follow-up period of 2 years appears 
to be insufficient compared to the literature, where long-term follow up has been reported 
in the analysis of outcomes.  In addition, a control group would have been desirable.  
However, this subset would ideally have comprised patients with severe functional tricuspid 
regurgitation undergoing left-sided valve surgery, in which tricuspid regurgitation was not 
addressed at the time of left-sided valve surgery.  Based on currently available evidence, 
failure to correct severe tricuspid regurgitation simultaneously would represent a departure 





















This study examined the results of simultaneous tricuspid valve surgery for severe 
functional tricuspid regurgitation in patients undergoing left-sided surgery for rheumatic 
valvular disease.   
Tricuspid valve  surgery was associated with a significant improvement in the following 
parameters at 6 weeks postoperatively:  NYHA functional class, tricuspid annular diameter, 
pulmonary artery systolic pressure, severity of tricuspid regurgitation and tricuspid 
transvalvular gradient.  Despite the encouraging immediate results of tricuspid valve 
surgery, the development of delayed severe residual postoperative tricuspid regurgitation 
unrelated to traditional risk factors may serve to diminish surgical enthusiasm for tricuspid 
valve repair in rheumatic valvular disease. 
The study hypothesis that preoperative pulmonary hypertension is associated with 
persistence and exacerbation of tricuspid regurgitation even after successful left-sided valve 
surgery was disproven.  We have shown that the presence of persistent postoperative 
pulmonary hypertension was not a major determinant of severe residual postoperative 
tricuspid regurgitation although it was associated with the occurrence of major adverse 
cardiovascular events (primary end-point). 
There were no identifiable predictors for the development of severe residual postoperative 
tricuspid regurgitation in this study and no relationship was demonstrated between the 
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development of severe residual postoperative tricuspid regurgitation and major adverse 
cardiovascular events (primary end-point).  
The underlying aetiology of left-sided valve pathology was rheumatic heart disease in the 
entire study population.  The preoperative evaluation of tricuspid regurgitation in these 
subjects suggested functional tricuspid regurgitation, however we have shown that 
rheumatic involvement of the tricuspid valve carried a potential for non-recognition of 
morphological abnormalities using standard two-dimensional transthoracic 
echocardiography.  This condition may also contribute to severe tricuspid regurgitation long 
after left-sided valve surgery.  Undiagnosed organic tricuspid valve disease may result in 
inappropriate selection of tricuspid valve repair techniques over tricuspid valve replacement 
procedures.  The results of tricuspid valve repair for organic disease are less favourable than 
those of repair procedures for functional tricuspid regurgitation, therefore it is imperative 
that organic tricuspid valve disease is elucidated preoperatively in order to dictate the most 
appropriate surgical intervention. 
There appeared to be a procedure selection bias towards tricuspid suture annuloplasty in 
the study, despite the published superiority of results obtained using the ring annuloplasty 
technique.  However, we could not demonstrate an association between the technique of 
tricuspid valve repair and the occurrence of major adverse cardiovascular events (primary 
end-point), or the development of severe residual postoperative tricuspid regurgitation 
(secondary end-point). 
This study shows that persistence of severe tricuspid regurgitation occurs in a substantial 
proportion of patients undergoing tricuspid valve repair, compromising surgical outcomes.  
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Analysis of the 2-year follow-up data demonstrated a satisfactory surgical outcome in only 
40% of the study population, the outcome being adversely influenced by the occurrence of 
severe residual postoperative tricuspid regurgitation (secondary end-point).  Multiple factors 
may be implicated, including the choice of annuloplasty technique and the sequelae of 
ongoing rheumatic tricuspid valve disease.  Outcomes may therefore be markedly influenced 
by the technique of perioperative imaging and the choice of annuloplasty procedure. 
This study suggests that the management of patients with functional tricuspid regurgitation 
of rheumatic aetiology should encompass surgical strategies which result in a lower 
incidence of severe residual postoperative tricuspid regurgitation, namely the routine use of 
preoperative three-dimensional and intraoperative transoesophageal echocardiography to 
comprehensively delineate valve morphology, as well as wider application of ring 
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